That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst

That key Gilead breast cancer readout? Try 2024, and don't get your hopes up: analyst

Source: 
Fierce Pharma
snippet: 

After coming short of declaring a clinically meaningful benefit for Trodelvy in stalling cancer progression or death in patients with pretreated HR-positive, HER2-negative breast cancer, Gilead is probably focusing on a final analysis of gold-standard patient survival data, RBC Capital Markets analyst Brian Abrahams said in a Tuesday note after speaking with Gilead’s investor relations team. That analysis is due in 2024.